Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar: financing pressure. About 7.6 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an at-the-market (ATM) program filed Feb 17, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$19.8MCash on Hand
7.6mo Cash Runway
25%Short Interest
$39.25Analyst Target (4)
Follow NRXP by emailGet an email when NRXP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NRXP, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Shareholder vote NRx Pharmaceuticals will hold its virtual-only 2026 annual meeting on December 17, 2026. Stockholders will vote to elect Dennis McBride as a Class II director and to ratify Weinberg & Company, P.A. as independent auditors for fiscal 2026. The Board unanimously recommends voting For both proposals. Form DEF 14A · SEC filing
Nov 2, 2026 ·
Regulatory FDA approved the company's ANDA for Preservative-Free Ketamine on October 30, 2026, ahead of the November 10, 2026 GDUFA goal date. The product is an American-manufactured presentation without benzethonium chloride, made with Nephron Pharmaceuticals in West Columbia, South Carolina. Form 8-K · SEC filing · Press release
Oct 16, 2026 ·
Shareholder vote Board set December 17, 2026 as the 2026 annual meeting date, to be held virtually, with an October 28, 2026 record date. Stockholder proposal and director nomination deadlines are October 25, 2026, and the Rule 14a-19 universal proxy notice deadline is October 26, 2026. Form 8-K · SEC filing
Oct 5, 2026 ·
Deal NRx Defense Systems, a subsidiary, won a DARPA prime contract worth about $11.2 million to run the SPARC-TMS trial of robotic TMS with NRX-101 for treatment-resistant depression. DARPA has initially obligated about $6.7 million, with the rest subject to appropriations and funding options. Form 8-K · SEC filing · Press release
Sep 16, 2026 ·
Regulatory FDA's Office of Generic Drugs reclassified the amendment to NRx's ANDA for preservative-free ketamine from Major to Minor, revising the GDUFA goal date to November 10, 2026. Form 8-K · SEC filing · Press release
Sep 14, 2026 ·
NRx Pharmaceuticals used an investor presentation, furnished as Exhibit 99.1, in meetings with investors on September 8, 2026. The filing gives no new data, numbers or deal terms. Form 8-K · SEC filing · Press release
Aug 17, 2026 ·
Earnings Reported a net loss of $18.0 million for the six months ended June 30, 2026, and an operating loss of $11.3 million, with cash of $26.7 million after a public offering of over $22 million. The ketamine ANDA received no major drug deficiencies, but one vial attestation is pending. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
2026-02-17 · PDUFA date · PDUFA Date Mentioned in 8-K Filing Disclosed by the company in an SEC filing
💰 Cash Runway & Dilution Risk
NRXP holds $19.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.8M/quarter from operations,
an estimated runway of 7.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:90 · High
Cash runway 8 months +30
ATM program on file since Feb 2026 +15
Shelf registration (S-3, Jun 2025) +10
Going-concern doubt in the latest 10-Q +15As such, the Company has concluded that substantial doubt exists regarding the Company’s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.10-Q, Nov 2026
Share count 44,327,982 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
📈 Recent Insider Activity (Form 4)
Trade date
Insider
Transaction
Shares
Price
Owned after
2026-07-28 filed 2026-11-04
ABRAMS MICHAEL S
Option award (A)
75,000
–
–
2026-07-28 filed 2026-11-04
Javitt Jonathan C
Option award (A)
150,000
–
–
2026-01-27 filed 2026-02-17
Casper Joseph Michael
Option award (A)
100,000
–
–
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
Get the full NRXP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NRXP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.